• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

RIBOCICLIB Drug Record

  • Summary
  • Interactions
  • Claims
  • RIBOCICLIB chembl:CHEMBL3545110 ApprovedAntineoplastic

    Alternate Names:

    LEE011
    LEE-011A
    NVP-LEE011
    RIBOCICLIB
    LEE-011
    pubchem.compound:44631912
    rxcui:1873916
    chembl:CHEMBL3545110
    drugbank:11730
    chemidplus:1211441-98-3

    Drug Info:

    Drug Class Kinase Inhibitors
    FDA Approval not approved
    Drug Class Small molecule
    Drug Indications antineoplastic agent
    FDA Approval Breast cancer (HR+, HER2-)
    Drug Class Small molecule inhibitor
    (8 More Sources)

    Publications:

    Rader et al., 2013, Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma., Clin. Cancer Res.
    Bortolozzi R et al., 2018, Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All)., Biochem Pharmacol
    Vora et al., 2014, CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors., Cancer Cell
    Vu et al., 2016, Targeting mutant NRAS signaling pathways in melanoma., Pharmacol. Res.
    Lee HJ et al., 2018, A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer., Cancer Lett
    Olanich ME et al., 2015, CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma., Clin Cancer Res
    Infante et al., 2016, A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas., Clin. Cancer Res.
    Dickson, 2014, Molecular pathways: CDK4 inhibitors for cancer therapy., Clin. Cancer Res.
    Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.
    Condorelli R et al., 2018, Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer., Ann Oncol
    Tripathy et al., 2017, Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors., Clin. Cancer Res.
    Xue Y et al., 2019, CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary., Nat Commun
  • RIBOCICLIB   CCND2

    Interaction Score: 1.93

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers

  • RIBOCICLIB   CDK6

    Interaction Score: 1.69

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cyclin-dependent kinase 6 inhibitor
    Direct Interaction yes
    Trial Name LEE011

    PMIDs:
    24045179 29408328


    Sources:
    MyCancerGenome TdgClinicalTrial ChemblInteractions CIViC TTD

  • RIBOCICLIB   CCND3

    Interaction Score: 1.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers

  • RIBOCICLIB   CDK4

    Interaction Score: 1.2

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name LEE011
    Novel drug target Novel Target
    Mechanism of Interaction Cyclin-dependent kinase 4 inhibitor

    PMIDs:
    24045179 29408328 25810375


    Sources:
    ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial ChemblInteractions CIViC TTD

  • RIBOCICLIB   SMARCA4

    Interaction Score: 1.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30718512


    Sources:
    CIViC

  • RIBOCICLIB   RB1

    Interaction Score: 1.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type T-cell adult acute lymphocytic leukemia
    Response Type resistant
    Approval Status Preclinical - Cell culture

    PMIDs:
    27542767 24795392 28151717 29236940


    Sources:
    JAX-CKB CIViC

  • RIBOCICLIB   CCND1

    Interaction Score: 0.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29306020


    Sources:
    ClearityFoundationBiomarkers CIViC

  • RIBOCICLIB   NOTCH1

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Ribociclib + Everolimus
    Indication/Tumor Type T-cell adult acute lymphocytic leukemia
    Response Type sensitive

    PMIDs:
    28151717


    Sources:
    JAX-CKB

  • RIBOCICLIB   CDKN2A

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers OncoKB

  • RIBOCICLIB   NRAS

    Interaction Score: 0.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Binimetinib + Ribociclib
    Evidence Type Actionable
    Approval Status Phase Ib/II

    PMIDs:
    26987942


    Sources:
    JAX-CKB CIViC OncoKB

  • RIBOCICLIB   PGR

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • RIBOCICLIB   BRAF

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Encorafenib + Ribociclib
    Indication/Tumor Type melanoma
    Response Type sensitive

    PMIDs:
    28351928


    Sources:
    JAX-CKB

  • RIBOCICLIB   ESR2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RIBOCICLIB   PIK3CA

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25002028


    Sources:
    CIViC

  • RIBOCICLIB   ERBB2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • RIBOCICLIB   ESR1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • MyCancerGenome: RIBOCICLIB

    • Version: 20-Jun-2017

    Alternate Names:
    KISQALI Trade Name

    Drug Info:
    Drug Class Small molecule inhibitor
    FDA Approval Breast cancer (HR+, HER2-)

    Publications:

  • MyCancerGenome: LEE011

    • Version: 20-Jun-2017

    Alternate Names:
    LEE011 Development Name

    Drug Info:
    Drug Class Kinase Inhibitors

    Publications:

  • TdgClinicalTrial: LEE011

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small molecule
    FDA Approval not approved

    Publications:

  • JAX-CKB: Ribociclib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Infante et al., 2016, A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas., Clin. Cancer Res.
    Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.
    Dickson, 2014, Molecular pathways: CDK4 inhibitors for cancer therapy., Clin. Cancer Res.

  • CIViC: RIBOCICLIB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Lee HJ et al., 2018, A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer., Cancer Lett
    Vu et al., 2016, Targeting mutant NRAS signaling pathways in melanoma., Pharmacol. Res.
    Vora et al., 2014, CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors., Cancer Cell

  • TTD: LEE011

    • Version: 2020.06.01

    Alternate Names:
    D08MXP TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL3545110

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationBiomarkers: LEE011

    • Version: 26-July-2013

    Alternate Names:

    Drug Info:

    Publications:

  • OncoKB: Ribociclib

    • Version: 23-July-2020

    Alternate Names:

    Drug Info:

    Publications:

  • PharmGKB: ribociclib

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL3545110

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Ribociclib

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21